Latest from Incanthera

Company Presentation at Hardman Lifescience Forum

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, is pleased to announce a Company presentation at the Hardman & Co. Lifesciences forum on 23 September 2021.

Chairman, Tim McCarthy and Chief Executive Officer, Simon Ward will give a presentation on the Company's current corporate status and activities, followed by a Q & A session.

The Lifesciences evening webinar will provide the opportunity for investors to hear an update on the Company's current corporate activities on its portfolio and near to market asset, Sol, an innovative skin cancer formulation. 

The live webinar will host three companies during the event, which can be accessed live at 5.00 p.m. on Thursday 23 September.

Shareholders and potential investors can register to join the webinar for free:

A copy of this notification is available via the company's website at

The directors of the Company take responsibility for this announcement.

For further information, please contact:

Incanthera plc

Tim McCarthy, Chairman
+44 (0) 7831 675747

Simon Ward, Chief Executive Officer
+44 (0) 7747 625506

Suzanne Brocks, Head of Communications
+44 (0) 7776 234600 

Notes to Editors

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics (“ICT”) at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: